Extra indication for VivaGel
Wednesday, 09 July, 2008
Melbourne biotech Starpharma [ASX: SPL] has announced plans to adapt the development of its vaginal microbicide VivaGel to incorporate the treatment of bacterial vaginosis.
VivaGel is currently in clinical trials as a prevention against the viruses such as HIV, genital herpes (HSV) and genital warts (HPV), and as a potential contraceptive. This is the first indication for which VivaGel might be used as a treatment.
Early tests suggest that VivaGel is able to reverse the imbalance between vaginal lactobacilli and disease-causing bacteria which is a characteristic of the condition.
Bacterial vaginosis is a major cause of vaginal infection, is implicated in pelvic inflammatory disease and may be associated with an increased risk of STIs and abortion.
Starpharma CEO Dr Jackie Fairley said the application was of interest because of its potential to open up new and rapid paths to market for VivaGel.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
